SightGlass Vision technology shows promising results for myopia control in young children

August 05, 2022

1 minute read

We were unable to process your request. Please try again later. If you continue to experience this issue, please contact [email protected]

Eyeglasses using SightGlass Vision diffusion optical technology significantly reduced the axial length and progression of cycloplegic spherical equivalent refraction in 6- to 7-year-old children with myopia, the company announced in a press release.

The lens technology, which incorporates thousands of light-scattering and contrast-reducing microdots on the retina, aims to slow the progression of myopia in children and has shown promising results in a recent analysis of clinical trial data. According to the statement, myopia affects more than 2.5 billion people worldwide and is the leading cause of visual impairment in children.

“Young myopic people can be difficult to manage for many reasons,” Andrew Sedgwick, CEO of SightGlass Vision, said in the statement. “Parents and eye care professionals have traditionally had a limited number of myopia control solutions for younger children.”

According to the release, analysis of 2-year interim data from the CYPRESS clinical trial, which includes 256 children at 14 clinical trial sites in the United States and Canada, suggests that “glasses enabled with SightGlass Vision diffusion optical technology offer a promising new approach to myopia control.” The participants, who were between 6 and 10 years old when they enrolled and had myopia between -0.75 D and -4.5 D, were randomized and provided with glasses at enrollment.The trial is now in its third year.

Leave a Comment